Physician profile
Stefanie Fox
NPI 1306407671
$3,991.31
in general payments reported to CMS, 2019-2025
27 companies · $1,025 in 2025
The $1,025 reported for 2025 was more than what 81% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $909 · 2022: $433 · 2023: $1,214 · 2024: $410 · 2025: $1,025.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,650.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,649.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $600.29 | 2021-2025 | Lybalvi, Aristada, Vivitrol |
| Abbvie INC. | $501.38 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $284.55 | 2021-2025 | Austedo, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $260.55 | 2023-2025 | Rexulti, Nuedexta |
| Biohaven Pharmaceuticals, INC. | $232.69 | 2021 | |
| Axsome Therapeutics, INC. | $217.25 | 2023-2024 | Auvelity |
| Neurocrine Biosciences, INC. | $208.40 | 2023-2025 | Ingrezza |
| Bayer Healthcare Pharmaceuticals INC. | $200.00 | 2021-2023 | |
| Indivior INC. | $183.60 | 2023-2025 | Sublocade |
| Idorsia Pharmaceuticals US INC | $124.99 | 2023 | Quviviq |
| Emd Serono, INC. | $124.99 | 2023 | |
| Urovant Sciences INC | $124.99 | 2022 | |
| Corium, LLC | $92.58 | 2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $87.54 | 2025 | Spravato, Invega Sustenna |
| Sk Life Science, INC. | $86.06 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $84.81 | 2022 | |
| Inspire Medical Systems, INC. | $82.70 | 2023 | Inspire |
| Collegium Pharmaceutical, INC. | $79.85 | 2025 | Jornay Pm |
| Biogen, INC. | $69.47 | 2023 | |
| Jazz Pharmaceuticals INC. | $58.33 | 2023 | |
| Amneal Pharmaceuticals LLC | $51.86 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $50.33 | 2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $49.09 | 2025 | Fanapt |
| Braeburn INC. | $48.65 | 2024-2025 | Brixadi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $42.02 | 2025 | Caplyta |
| Lundbeck LLC | $29.57 | 2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $14.77 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stefanie Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.